Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Orexigen Therapeutics, Inc.OREX · Entity 157016 | Director · CEO & President | October 13, 2017 | October 17, 2017 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Orexigen Therapeutics, Inc.
Report date October 13, 2017 · Filed October 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 252,000 |
Reported balance
After 2017-10-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-13 · Grant · Acquired 252,000 · Balance 252,000 F1: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2: Reflects an award of restricted stock units ("RSUs"), each representing a contingent right to receive a share of the issuer's common stock upon settlement. F3: Twenty-five percent (25%) of the RSUs will vest on each of the first four (4) anniversaries of February 3, 2018 (each, a "Vesting Date"), subject to the reporting person's continued eigibility on each applicable Vesting Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
F2: Reflects an award of restricted stock units ("RSUs"), each representing a contingent right to receive a share of the issuer's common stock upon settlement.
F3: Twenty-five percent (25%) of the RSUs will vest on each of the first four (4) anniversaries of February 3, 2018 (each, a "Vesting Date"), subject to the reporting person's continued eigibility on each applicable Vesting Date.
Ultragenyx Pharmaceutical Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,441 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 7,751 · Balance 40,441 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.80 · Expires 2036-05-14 | Direct | 14,058 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 14,058 · Balance 14,058 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 18, 2026 18:35 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 14,058 | $0.00 Strike: $25.80 | $0.00 |
DisclosureSEC source: 0001380022-26-000002 · ownership.xml · derivative · entry 2 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,058 Underlying: Common Stock · 14,058 shares Expires 2036-05-14 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Read SEC document |
| May 14, 2026 Filed May 18, 2026 18:35 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 7,751 | $0.00 | $0.00 |
DisclosureSEC source: 0001380022-26-000002 · ownership.xml · nonDerivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,441 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Read SEC document |
| May 15, 2025 Filed May 19, 2025 18:32 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 10,787 | $0.00 Strike: $34.84 | $0.00 |
DisclosureSEC source: 0000950170-25-074665 · ownership.xml · derivative · entry 2 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,787 Underlying: Common Stock · 10,787 shares Expires 2035-05-15 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. Read SEC document |
| May 15, 2025 Filed May 19, 2025 18:32 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,740 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074665 · ownership.xml · nonDerivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,690 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 14:24 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 9,900 | $0.00 Strike: $37.42 | $0.00 |
DisclosureSEC source: 0000950170-24-075487 · ownership.xml · derivative · entry 2 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,900 Underlying: Common Stock · 9,900 shares Expires 2034-06-18 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 14:24 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,345 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-075487 · ownership.xml · nonDerivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,950 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 14:30 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock · Derivative | 7,110 | $0.00 Strike: $51.82 | $0.00 |
DisclosureSEC source: 0001209191-23-035688 · doc4.xml · derivative · entry 2 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 7,110 shares Expires 2033-06-07 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 14:30 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035688 · doc4.xml · nonDerivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,605 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 13:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 6,245 | $0.00 Strike: $60.57 | $0.00 |
DisclosureSEC source: 0001209191-22-039565 · doc4.xml · derivative · entry 2 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,245 Underlying: Common Stock · 6,245 shares Expires 2032-06-24 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 13:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039565 · doc4.xml · nonDerivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,745 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 18:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $93.20 | $0.00 |
DisclosureSEC source: 0001209191-21-043538 · doc4.xml · derivative · entry 2 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,125 Underlying: Common Stock · 4,125 shares Expires 2031-06-24 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 18:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043538 · doc4.xml · nonDerivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,445 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 13:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 4,250 | $0.00 Strike: $76.58 | $0.00 |
DisclosureSEC source: 0001209191-20-039407 · doc4.xml · derivative · entry 2 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires 2030-06-26 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 26, 2021. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 13:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039407 · doc4.xml · nonDerivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,300 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 26, 2021 Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 16:46 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $58.74 | $0.00 |
DisclosureSEC source: 0001209191-19-036816 · doc4.xml · derivative · entry 2 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-06-11 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 11, 2020. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 16:46 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036816 · doc4.xml · nonDerivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,750 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 11, 2020. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 18:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $80.69 | $0.00 |
DisclosureSEC source: 0001209191-18-038857 · doc4.xml · derivative · entry 2 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-06-19 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 19, 2019. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 18:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038857 · doc4.xml · nonDerivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 19, 2019. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 19:16 UTC | Orexigen Therapeutics, Inc. OREX · Entity 157016 | GrantRestricted Stock Unit (RSU) · Derivative | 252,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-057217 · doc4.xml · derivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,000 Underlying: Common Stock · 252,000 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2 · shares: Reflects an award of restricted stock units ("RSUs"), each representing a contingent right to receive a share of the issuer's common stock upon settlement. F3 · derivative.exercise_date: Twenty-five percent (25%) of the RSUs will vest on each of the first four (4) anniversaries of February 3, 2018 (each, a "Vesting Date"), subject to the reporting person's continued eigibility on each applicable Vesting Date. F3 · derivative.expiration_date: Twenty-five percent (25%) of the RSUs will vest on each of the first four (4) anniversaries of February 3, 2018 (each, a "Vesting Date"), subject to the reporting person's continued eigibility on each applicable Vesting Date. Read SEC document |
| June 22, 2017 Filed Jun 22, 2017 19:26 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $65.66 | $0.00 |
DisclosureSEC source: 0001209191-17-041474 · doc4.xml · derivative · entry 2 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2027-06-22 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018. Read SEC document |
| June 22, 2017 Filed Jun 22, 2017 19:26 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041474 · doc4.xml · nonDerivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 16:55 UTC | Orexigen Therapeutics, Inc. OREX · Entity 157016 | GrantCommon Stock | 626 | $1.55 | $970.30 |
DisclosureSEC source: 0001209191-17-037346 · doc4.xml · nonDerivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,356 F1 · acquired: Shares acquired under Issuer's 2013 Employee Stock Purchase Plan. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 06:51 UTC | Orexigen Therapeutics, Inc. OREX · Entity 157016 | GrantStock Option · Derivative | 157,500 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001209191-17-008202 · doc4.xml · derivative · entry 2 NARACHI MICHAEL · CIK 0001380022 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,500 Underlying: Common Stock · 157,500 shares Expires 2027-02-02 F2 · price: Not Applicable F1 · derivative.exercise_date: 1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month following 2/3/2017, so that all of the shares of the stock subject to the option shall be vested on 2/3/2021, subject to the Reporting Person's continued service relationship (whether as an employee, director or consultant) with the Issuer or any parent or subsidiary on each such date, as set forth in the applicable stock option grant notice and stock option agreement for such Reporting Person. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 06:51 UTC | Orexigen Therapeutics, Inc. OREX · Entity 157016 | GrantStock Option · Derivative | 315,000 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0001209191-17-008202 · doc4.xml · derivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,000 Underlying: Common Stock · 315,000 shares Expires 2027-02-02 F2 · price: Not Applicable F1 · derivative.exercise_date: 1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month following 2/3/2017, so that all of the shares of the stock subject to the option shall be vested on 2/3/2021, subject to the Reporting Person's continued service relationship (whether as an employee, director or consultant) with the Issuer or any parent or subsidiary on each such date, as set forth in the applicable stock option grant notice and stock option agreement for such Reporting Person. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 17:11 UTC | Orexigen Therapeutics, Inc. OREX · Entity 157016 | GrantCommon Stock | 802 | $1.67 | $1,339.34 |
DisclosureSEC source: 0001209191-16-153095 · doc4.xml · nonDerivative · entry 1 NARACHI MICHAEL · CIK 0001380022 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,312 F1 · acquired: Shares acquired under Issuer's 2013 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.